Posts

Showing posts from May, 2017

Research report explores the Laxatives Market Forecast to 2022 - By Credence Research

Image
The latest market report published by Credence Research, Inc. “Global Laxatives Market Size - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the laxatives market was valued at USD 4,739.42 Mn in 2015, and is expected to reach USD 6,948.07 Mn by 2022, expanding at a CAGR of 5.6% from 2016 to 2022.

Market Insights
Constipation is among the most common gastrointestinal malfunctions observed across all age groups. The prevalence of constipation in the general population is between 0.7% to 79% (with a median at 16%) (Epidemiology of constipation in children and adults: a systematic review, 2010), across all age groups. Constipation prevalence is high among the geriatric population and higher in females. The median province of constipation among children is 12%. With the growing burden of the condition there is a constant struggle among care givers and drug manufacturers to come up with more evolved treatment options.

Browse the full report Global Laxatives Mar…

Research report explores the Irritable Bowel Syndrome with Diarrhea Drugs Market Forecast to 2022 - By Credence Research

Image
The latest market report published by Credence Research, Inc. “Global Irritable Bowel Syndrome with Diarrhea Market Size - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the irritable bowel syndrome with diarrhea (IBS-D) drugs market was valued at USD 289.3 Mn in 2015, and is expected to reach USD 1,115.06 Mn by 2022, expanding at a CAGR of 13.89% from 2016 to 2022.

Market Insights
Recent approvals for two new prescription drugs to treat irritable bowel syndrome with diarrhea (IBS-D) have become the biggest phenomenon in the IBS-D drugs market. These approvals are viewed as breakthrough step in the long struggle to discover effective treatment for IBS-D.
Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora. Xifaxan had been used off label for treating IBS-D, thus direct approval for treating IBS-D will lead to growth in demand …

Research report explores the Opioid Induced Constipation Drugs Market Forecast to 2022 - By Credence Research

Image
The latest market report published by Credence Research “Global Opioid Induced Constipation Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the opioid induced constipation drugs market was valued at USD 1,933.2 Mn in 2015, and is expected to reach USD 2,779.24 Mn by 2022, expanding at a CAGR of 4.6% from 2016 to 2022.

Market Insights
Alarming growth in opioid prescription for non-cancer pain has been a phenomenal event in the previous decade. As per the recent estimates, more than 40% of opioid consumers experience constipation and GI symptoms as side effects of opioid drugs. Rising pool of opioid users will lead to the growth in opioid induced constipation (OIC) prevalence thus contributing to OIC drugs market growth. The global opioid induced constipation drugs market was valued at USD 1,933.2 Mn in 2014 and is expected to reach USD 2,779.2 Mn by 2022 with the market growing at a CAGR of 4.6% during 2016-2022.

Browse the full report Opioid…

Research report explores the Chronic Idiopathic Constipation Drugs Market Forecast to 2022 - By Credence Research

Image
The latest market report published by Credence Research, Inc. “Global Chronic Idiopathic Constipation Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the chronic idiopathic constipation drugs market was valued at USD 1675.4 Mn in 2015, and is expected to reach USD 2570.8 Mn by 2022, expanding at a CAGR of 6.4% from 2016 to 2022.


Market Insights
Growing awareness and increasing incidence and prevalence of chronic idiopathic constipation – CIC are the major factors driving the CIC drugs market worldwide. Growth in demand for CIC drugs in Asia Pacific, coupled with the huge gap of unmet needs in the region is expected to serve as a significant opportunity in the global market during forecast period.

In terms of geographical distribution, North America captures over 40% share of the global market revenue. US is the largest national market for CIC  drugs due to greater prevalence of lifestyle respective diseases, higher incidence of constipation…